7 results about "Mouse Hippocampus" patented technology

This invention provides the application of *Ackermania guangxiensis* extracellular polysaccharide in the preparation of anti-aging products, belonging to the technical field of microbial polysaccharide pharmaceutical applications. This invention extracts extracellular polysaccharides from *Ackermania guangxiensis* using the TCA precipitation method. Animal experiments show that *Ackermania guangxiensis* extracellular polysaccharide can effectively reduce MDA content in aging model mice while increasing SOD activity; it improves the thinning of the dermal layer, reduction and loosening of collagen fibers, and other signs of aging in model mice, and increases the hydroxyproline content in the skin; furthermore, it can activate the expression of BDNF and TrKB genes in the mouse hippocampus and alleviate problems such as slow movement, cognitive impairment, and memory decline in model mice. Therefore, the *Ackermania guangxiensis* extracellular polysaccharide provided by this invention has good anti-aging and antioxidant activity and can be used to prepare various anti-aging products.

The application relates to the technical field of medicines, and particularly discloses a polypeptide and application of the polypeptide in preparation of a medicine for ischemic stroke. The amino acid sequence of the polypeptide is as shown in SEQ ID NO. 1. The polypeptide can significantly improve the nerve function defect of a mouse transient middle cerebral artery occlusion / reperfusion (tMCAO / R) model in vivo, reduce the cerebral infarction volume, and reduce the whole-body oxidative stress level. In vitro, the polypeptide has a direct protective effect on HT22 cells of mouse hippocampal neurons and hCMEC / D3 cells of human brain microvascular endothelium induced by oxygen-glucose deprivation (OGD), can resist the damage of corticosterone and MPP + induced PC12 cells, and effectively inhibits the accumulation of reactive oxygen species (ROS) in cells. The results show that the polypeptide has a multi-target cell protection activity, can play an anti-ischemic stroke role from multiple dimensions such as reduction of infarction volume, inhibition of oxidative stress level, and protection of nerve vascular units.

The application belongs to the field of medicine and relates to application of an isoflavone compound, isoformononetin (IFM), in preparation of a medicine or health care product for preventing and treating depression; in mouse hippocampal neuron cells (HT22) or mouse microglial cells (BV2), IFM can reduce neuroinflammation caused by corticosterone (CORT) or lipopolysaccharide (LPS) and increase the expression level of brain-derived neurotrophic factor (BDNF); in a chronic mild unpredictable stress mouse depression model, IFM can relieve depression-like behavior of the mouse and reduce the inflammation level of brain tissue, indicating that IFM has a good effect of relieving depression; IFM degrades PDE4D protein by directly combining with a PDE4D target protein. The isoflavone compound IFM has the advantages of outstanding effect and high safety and is expected to develop into an effective medicine for treating and preventing depression.

The application discloses a target strategy and a drug intervention method for improving Primrose syndrome, and belongs to the technical field of biological medicine. The experiment proves that Momordin Ic can significantly improve the SUMO level of ZBTB20 in vitro cells or Primrose syndrome (PS) mice, can effectively improve the defects of reduced neuron dendritic branching in the hippocampal CA1 region of the PS mice in pathology, can enhance the complexity, and can improve the cognitive and emotional disorders such as memory impairment and anxiety-like behavior of the PS mice to different degrees in behavior. The application discloses that Momordin Ic can improve the PS-related neuropathological changes and behavioral cognitive defects by targeting the SENP1-ZBTB20-SUMO pathway, and provides a new candidate molecule and a clear action target for developing potential therapeutic drugs for Primrose syndrome.

The application discloses application of methyl palmitate in preparation of a medicine for treating and / or preventing senility and related cognitive impairment, and belongs to the technical field of biological medicine. The application proves by a cell experiment that methyl palmitate can significantly inhibit D-galactose-induced SH-SY5Y cell senility, and effectively reduce the expression level of senility-related proteins P53 and P16. The application proves by a behavior experiment that methyl palmitate can significantly improve the cognitive index of a senility model mouse, shorten an escape latency, and effectively improve learning ability reduction, spatial memory decline and cognitive function impairment caused by senility. In addition, methyl palmitate can significantly enhance the long-term potentiation effect of the hippocampal CA1 region of the senility model mouse, and reverse senility-related synaptic transmission damage. The application discloses the application of methyl palmitate in resisting neural senility and improving senility-related cognitive impairment, and provides a new candidate molecule for preparing a medicine for treating neurodegenerative diseases.

This invention discloses a 3-hydroxypyridinone derivative, its preparation method, and its applications. This 3-hydroxypyridinone derivative, through structural modification of the 3-hydroxypyridinone core, significantly enhances its anti-ferroptosis activity against hippocampal neurons in HT-22 mice. In vitro experiments show that its inhibitory effect on ferroptosis is more than twice that of the positive control deferoxone. Furthermore, the 3-hydroxypyridinone derivative can also chelate Fe... 3+ To alleviate iron-mediated Aβ 1‑42 Protein aggregation and its cytotoxicity. This invention also provides synthetic routes, purification methods, and in vitro activity evaluation systems for 3-hydroxypyridinone derivatives, offering structural optimization strategies and candidate compounds for the development of drugs targeting iron metabolism disorders.

This invention provides lactylated PRDX5 protein, its products, and applications, belonging to the field of biomedical technology. This invention reveals the crucial role of PRDX5 K71 site lactylation modification in the pathological process of COPD, showing abnormally elevated levels of lactylation in hippocampal neurons of COPD mice, which is closely related to the occurrence and development of cognitive impairment in mice. Simultaneously, it provides a specific intervention protocol targeting this site. Stereoscopic injection of recombinant adeno-associated virus PRDX5 K71R mutant reduces or blocks the likelihood of lactylation modification at the K71 site, effectively improving learning, memory, and spatial orientation abilities in COPD mice. This provides new molecular targets and experimental evidence for the study of the mechanisms of cognitive impairment and targeted prevention and treatment.